StemCell Therapy

S2.4 - Session 2: Determine the tissue and cellular sources of persistent HIV...
Session 2: Determine the tissue and cellular sources of persistent HIV in long-term ART-treated individuals Abstract presentation S2.4 -- T memory stem cells: a long-term reservoir for HIV-1 Presenter: Maria Jose Buzon, Ragon Institute of MGH, MIT and Harvard, Massachussetts General Hospital, United States "Towards an HIV Cure", AIDS 2012 Pre-Conference Symposium, Washington DC, July 2012From:iasocietyViews:5 0ratingsTime:16:43More inScience Technology

View original post here:
S2.4 - Session 2: Determine the tissue and cellular sources of persistent HIV... - Video

Stem Cells: The View of a Scientist
A film about stem cells that we created for our biology project. Enjoy.From:TDProductions2015Views:0 1ratingsTime:07:32More inEducation

See more here:
Stem Cells: The View of a Scientist - Video

Stem Cells For Kids
From:toshironinja13Views:1 0ratingsTime:01:37More inPeople Blogs

See the original post here:
Stem Cells For Kids - Video

What is the Proceedure to Inject Stem Cells to treat Lyme Disease
From:Earle JuddViews:6 0ratingsTime:02:11More inPeople Blogs

Read the original here:
What is the Proceedure to Inject Stem Cells to treat Lyme Disease - Video

Macquarie Stem Cells Channel 7 Today Tonight
From:Bugra SagmanViews:0 0ratingsTime:04:15More inPeople Blogs

Read this article:
Macquarie Stem Cells Channel 7 Today Tonight - Video

Glyco finder Dr. McAnalley in Mannatech(Health/ stem cells / disease / nutrients / heartattack)
From:Glyco MannatechViews:0 0ratingsTime:17:46More inNonprofits Activism

See original here:
Glyco finder Dr. McAnalley in Mannatech(Health/ stem cells / disease / nutrients / heartattack) - Video

R. Bolli - Interim Results of the SCIPIO Trial Up to 2 Years After Therapy
R. Bolli - Effect of Cardiac Stem Cells in Patients with Ischemic Cardiomyopathy: Interim Results of the SCIPIO Trial Up to 2 Years After Therapy SCIPIO: (Cardiac) Stem Cell Infusion in Patients with Ischemic cardiomyopathy Annual Session of the American Heart Association November 5, 2012, Los AngelesFrom:CardioletterViews:0 0ratingsTime:09:07More inScience Technology

Excerpt from:
R. Bolli - Interim Results of the SCIPIO Trial Up to 2 Years After Therapy - Video

David Gamm on Stem Cell Research
Dr. David Gamm, associate professor of ophthalmology and visual sciences at the University of Wisconsin School of Medicine and Public Health in Madison and director of the McPherson Eye Research Institute, discusses the use of stem cells for eye diseases.From:UWMedicineViews:16 0ratingsTime:03:15More inEntertainment

Originally posted here:
David Gamm on Stem Cell Research - Video

Notch Signalling
ll4.me Notch Signalling International authors provide researchers with an overview and synthesis of the latest research findings and contemporary thought in the area of Notch Signaling.Covers topics such as Notch signaling in Cardiac development and disease, and Notch in Stem Cells. International authors provide researchers with an overview and synthesis of the latest research findings and contemporary thought in the area. Publisher: Academic Press Illustration: N Language: ENG Title: Notch Signalling Pages: 00548 (Encrypted PDF) On Sale: 2010-09-01 SKU-13/ISBN: 9780123809148 Category: Medical : General Category: Science : Life Sciences - Molecular Biology Category: Science : Life Sciences - Cell Biology International authors provide researchers with an overview and synthesis of the latest research findings and contemporary thought in the area of Notch Signaling.Covers topics such as medical, general, science, life sciences, molecular biologyFrom:irishughes9854Views:0 0ratingsTime:00:08More inPeople Blogs

Read more:
Notch Signalling - Video

Dr. Tommy Mitchell Stem Cells Cloning Immanuel Baptist Church Highland, CA. November 5, 2012
At 44:00 Min he accidentally says "Is using Adult Stem Cells Wrong? Yes. He should have said Embryonic Stem Cells. ; ) Dr. Tommy Mitchell Lecture on Stem Cells Cloning at Immanuel Baptist Church Highland, CA. November 5, 2012 Dr. Mitchell graduated with a BA with highest honors from the University of Tennessee, Knoxville, in 1980, with a major in Cell Biology and a minor in Biochemistry. For his superior scholarship during his undergraduate study, he was elected to Phi Beta Kappa Society (the oldest and one of the most-respected honor societies in America). Dr. Mitchell subsequently attended Vanderbilt University School of Medicine in Nashville, where he received his medical degree in 1984. Dr. Mitchell completed his residency at Vanderbilt University Affiliated Hospitals in 1987. He is Board Certified in Internal Medicine. In 1991, he was elected a *Fellow of the American College of Physicians (FACP). Tommy had a thriving medical practice in his hometown of Gallatin, Tennessee, for 20 years, but, in late 2006, he withdrew from medical practice to pursue creation ministry full time.From:MClover420Views:0 0ratingsTime:01:00:01More inEducation

Read the rest here:
Dr. Tommy Mitchell Stem Cells

Current Medication after Stem Cells
From:Earle JuddViews:0 0ratingsTime:00:43More inPeople Blogs

Excerpt from:
Current Medication after Stem Cells - Video

LOS ANGELES Researchers are reporting a key advance in using stem cells to repair hearts damaged by heart attacks. In a study, stem cells donated by strangers proved as safe and effective as patients own cells for helping restore heart tissue.

The work involved just 30 patients in Miami, but proves the concept that anyones cells can be used to treat such cases. Doctors are excited because this suggests that stem cells could be banked for off-the-shelf use after heart attacks, just as blood is kept on hand now.

Results were discussed Monday at an American Heart Association conference in California and published in the Journal of the American Medical Association.

The study used a specific type of stem cells from bone marrow that researchers believed would not be rejected by recipients. Unlike other cells, these lack a key feature on their surface that makes the immune system see them as foreign tissue and attack them, explained the studys leader, Dr. Joshua Hare of the University of Miami.

The patients in the study had suffered heart attacks years earlier, some as long as 30 years ago. All had developed heart failure because the scar tissue from the heart attack had weakened their hearts so much that they grew large and flabby, unable to pump blood effectively.

Researchers advertised for people to supply marrow, which is removed using a needle into a hip bone. The cells were taken from the marrow and amplified for about a month in a lab at Baltimores Johns Hopkins University, then returned to Miami to be used for treatment, which did not involve surgery.

The cells were delivered through a tube pushed through a groin artery into the heart near the scarred area. Fifteen patients were given cells from their own marrow and 15 others, cells from strangers.

About a year later, scar tissue had been reduced by about one-third. Both groups had improvements in how far they could walk and in quality of life. There was no significant difference in one measure of how well their hearts were able to pump blood, but doctors hope these patients will continue to improve over time, or that refinements in treatment will lead to better results.

The big attraction is being able to use cells supplied by others, with no blood or tissue matching needed.

You could have the cells ready to go in the blood bank so when the patient comes in for a therapy theres no delay, Hare said. Its also cheaper to make the donor cells, and a single marrow donor can supply enough cells to treat as many as 10 people.

See the original post:
Stem cells from strangers can help fix hearts, study finds

Stem cells harvested from the bone marrow of healthy donors proved as effective as those derived from the patients themselves, a study found Of 30 people that had previously suffered a heart attack, half were treated with their own stem cells and half with cells from donors In both groups scar tissue was reduced by 33 per cent Researchers say the use of donor cells could speed up treatment

By Kerry Mcdermott

PUBLISHED: 14:51 EST, 6 November 2012 | UPDATED: 05:58 EST, 7 November 2012

Stem cells culled from the bone marrow of healthy donors work as well as cells harvested from patients themselves as a treatment for damaged hearts, research has revealed.

The 13-month trial compared the safety and effectiveness of stem cells derived from the bone marrow of patients themselves to those provided by donors in the treatment of people suffering the after-effects of a heart attack.

The donor stem cells proved as effective as the patient stem cells in reducing scar tissue - a result researchers called 'very, very significant'.

Scientists are now exploring the use of stem cells to treat heart disease and other ailments (file photo)

Researchers have said the discovery that donor cells are as safe and effective as the recipients' own cells could potentially improve the treatment further by speeding it up, as doctors could draw on a bank of donor cells to administer to heart patients immediately.

Adult stem cells that renew themselves and mature into specific cell types have been used for 40 years in bone marrow transplants.

Visit link:
Stem cells taken from a healthy donor may work better for treating heart patients than cells taken from their own tissue

U-M, UCSF researchers coax cells to grow and myelinate along thin fibers, with potential use in testing treatments for neurological diseases

Newswise ANN ARBOR, Mich. Every week in his clinic at the University of Michigan, neurologist Joseph Corey, M.D., Ph.D., treats patients whose nerves are dying or shrinking due to disease or injury.

He sees the pain, the loss of ability and the other effects that nerve-destroying conditions cause and wishes he could give patients more effective treatments than whats available, or regenerate their nerves. Then he heads to his research lab at the VA Ann Arbor Healthcare System, where his team is working toward that exact goal.

In new research published in several recent papers, Corey and his colleagues from the U-M Medical School, VAAAHS and the University of California, San Francisco report success in developing polymer nanofiber technologies for understanding how nerves form, why they dont reconnect after injury, and what can be done to prevent or slow damage.

Using polymer nanofibers thinner than human hairs as scaffolds, researchers coaxed a particular type of brain cell to wrap around nanofibers that mimic the shape and size of nerves found in the body.

Theyve even managed to encourage the process of myelination the formation of a protective coating that guards larger nerve fibers from damage. They began to see multiple concentric layers of the protective substance called myelin start to form, just as they do in the body. Together with the laboratory team of their collaborator Jonah Chan at UCSF, the authors reported the findings in Nature Methods.

The research involves oligodendrocytes, which are the supporting actors to neurons -- the stars of the central nervous system. Without oligodendrocytes, central nervous system neurons cant effectively transmit the electrical signals that control everything from muscle movement to brain function.

Oligodendrocytes are the type of cells typically affected by multiple sclerosis, and loss of myelin is a hallmark of that debilitating disease.

The researchers have also determined the optimum diameter for the nanofibers to support this process giving important new clues to answer the question of why some nerves are myelinated and some arent.

While they havent yet created fully functioning nerves in a dish, the researchers believe their work offers a new way to study nerves and test treatment possibilities. Corey, an assistant professor of neurology and biomedical engineering at the U-M Medical School and researcher in the VA Geriatrics Research, Education and Clinical Center, explains that the thin fibers are crucial for the success of the work.

See the original post here:
Stem Cells + Nanofibers = Promising Nerve Research

Public release date: 7-Nov-2012 [ | E-mail | Share ]

Contact: Deborah Mann Lake deborah.m.lake@uth.tmc.edu 713-500-3030 University of Texas Health Science Center at Houston

HOUSTON (Nov. 7, 2012) Administering stem cells derived from patients' own bone marrow either three or seven days after a heart attack is safe but does not improve heart function six months later, according to a clinical trial supported by the National Institutes of Health (NIH).

The results of the trial, called Transplantation In Myocardial Infarction Evaluation (TIME), mirror a previous related study, LateTIME, which found that such cells (called autologous stem cells) given two to three weeks after a heart attack did not improve heart function. Both TIME and LateTIME were conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), sponsored by the NIH's National Heart, Lung, and Blood Institute.

The findings were presented Nov. 6, 2012, at the American Heart Association 2012 Scientific Sessions in Los Angeles and appeared concurrently in the Journal of the American Medical Association.

"These cells, while safe, were not better than placebo solution in providing benefit," said Lemuel Moy, III, M.D., Ph.D., principal investigator of the CCTRN and professor of biostatistics at The University of Texas School of Public Health, part of The University of Texas Health Science Center at Houston (UTHealth). "While this one cell type showed little promise, there are several new cell types that are available and we will be studying them. Cell therapy can and likely will play a major role in the treatment of cardiovascular disease in the future."

"This study was extremely valuable even though it did not provide a demonstrated health benefit after six months," said Sonia Skarlatos, Ph.D., deputy director of NHLBI's Division of Cardiovascular Sciences and member of the CCTRN. "Heart stem cell therapy research is still in its infancy, and results from early trials have varied greatly due to differences in the numbers of stem cells injected, the delivery methods used, and the compositions of the study populations. With TIME and LateTIME, we have established both safety and baseline results in two large studies that followed the same procedures for growing and then administering stem cells. This standard will inform the next steps in research on the use of stem cells to repair damaged hearts."

Skarlatos noted that another advantage of the TIME study is that CCTRN is storing samples of the stem cells taken from the participants. Investigators can examine the relationship between people who showed significant improvement during the study and the characteristics of their stem cells. Such a comparison may offer insights on the cell traits that are associated with clinical improvement.

Between July 2008 and February 2011, TIME researchers enrolled 120 volunteers (average age 57, 87.5 percent male) who suffered from moderate to severe impairment in their left ventricles the part of the heart that pumps oxygen-rich blood to the body and had undergone stenting procedures following heart attacks. Those selected for the trial were assigned randomly to one of four groups: day three after heart attack stem cell injection, day three after heart attack placebo injection, day seven after heart attack stem cell treatment, or day seven after heart attack placebo treatment. The researchers developed a method of processing and purifying the stem cells to ensure that participants in the stem cell groups received a uniform dose of 150 million cells about eight hours after the cells were harvested from their bone marrow. This ensured that results would not be skewed by differences in the quantity or quality of stem cells administered.

Researchers assessed heart improvement six months after stem cell therapy by measuring the percentage of blood that was pumped out of the left ventricle during each contraction (known as the left-ventricular ejection fraction, or LVEF). The study found no significant differences between the change in LVEF readings at the six-month follow-up in either the day three or the day seven stem cell groups compared with placebo groups or with each other. Every group showed about a three percent improvement in LVEF.

Original post:
Bone marrow stem cells do not improve short-term recovery after heart attack

A small study suggests that stem cells can help repair the damage of a heart attack, and it doesn't matter if the cells originate with the patient or a stranger.

The study, which involved just 30 patients, is the first involving a certain type of cells, called mesenchymal stem cells, that compares outcomes depending on whether the cells came from the patient or a donor.

Across most measures -- including reductions in cardiac scar tissue, patient quality of life and safety -- people got the same benefit regardless of where the stem cells came from, researchers reported Monday at the annual meeting of the American Heart Association in Los Angeles. The study is also being published online Nov. 6 in the Journal of the American Medical Association.

"We believe the basic message of the study is that this procedure is safe and that future, larger studies are warranted," lead study author Dr. Joshua Hare, director of the Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine, said at a news briefing.

Millions of people around the world suffer from heart failure, often caused by a heart attack that severely damaged heart muscle at some point in the past. This can cause hearts to become enlarged and weakened, a condition called ischemic cardiomyopathy.

Unfortunately, progress against heart failure has been stalled for decades. But recently, scientists have been introducing stem cells, which can turn into cardiac cells, into the hearts of these patients, to see if they might repair the damage.

In most cases, the cells have been sourced from the patients themselves, but that presents its own problems. Speaking at the news briefing, Stefanie Dimmeler, head of the section of molecular cardiology at the University of Frankfurt, Germany, explained that it takes up to two months to grow the millions of stem cells needed for transplant. If a patient suffers a heart attack and needs them quickly, it is just not feasible to use his or her own cells.

"So," said Dimmeler, who was not involved in the new study, "it might be interesting to have cells 'off-the-shelf'" that were grown earlier, using an outside donor's cells.

But would these donor cells perform as well as the patient's own?

In the new study, Hare and his colleagues investigated that question with 30 patients who all had damaged, enlarged hearts due to a prior heart attack. Half received infusions of their own mesenchymal stem cells, while the other half received cells sourced from young, healthy donors. The patients were then tracked for 13 months.

See the article here:
Stem cells from donor may help heal heart

By E.J. Mundell HealthDay Reporter

TUESDAY, Nov. 6 (HealthDay News) -- Updated two-year results from a small trial using cardiac stem cells to repair damaged hearts suggest the treatment's healing effect persists.

Patients with heart failure caused by prior heart attacks who got the treatment continue to see reductions in cardiac scar tissue, improvements in the heart's pumping ability and even a boost in their quality of life, researchers said.

These improvements seem to be continuing as time goes on, suggesting that stem cell therapy's healing power hasn't diminished.

"Now we need to perform larger and randomized, blinded studies ... to confirm this data," said study lead author Dr. Roberto Bolli, director of the Institute of Molecular Cardiology at the University of Louisville.

His team presented its results Tuesday at the American Heart Association's annual meeting, in Los Angeles.

According to the AHA, more than 6 million Americans suffer from heart failure, a gradual weakening of the heart often caused by damage from a prior heart attack. Despite its prevalence and lethality, virtually no advance has been made over the past few decades in doctors' ability to treat or reverse heart failure.

That's why the advent of stem cell therapy has encouraged researchers. Stem cells have the ability to turn into myriad living cells, and the hope is that once infused into the heart they can help repair it.

This trial is the first human trial to test this theory using the patient's own cardiac stem cells. The cells used in the trial were harvested from 33 heart failure patients who were undergoing bypass surgery. The cells were then coaxed to multiply into the millions in the lab and then transplanted back into 20 of the patients. The remaining 13 patients did not receive a stem cell infusion and are the "control" group for comparison purposes.

Results gathered one year after treatment showed improvements for the treated patients, but experts questioned whether those gains would fade over time.

Excerpt from:
Two Years On, Stem Cells Still Healing Damaged Hearts

Study Highlights:

LOS ANGELES, Nov. 6, 2012 (GLOBE NEWSWIRE) -- Cardiac stem cells may one day be an effective treatment for heart failure caused by muscle scarring after a heart attack, according to late-breaking clinical trial results presented at the American Heart Association's Scientific Sessions 2012.

In the Effect of Cardiac Stem Cells In Patients with Ischemic CardiOmyopathy (SCIPIO) trial, heart function and quality of life improved in 20 people treated with their own cardiac stem cells (CSCs).

"This is exciting," said Roberto Bolli, M.D., lead author of the trial, chief of Cardiovascular Medicine and director of the Institute of Molecular Cardiology at the University of Louisville in Kentucky. "The effect of these cells has continued for up to two years, and has gotten stronger. There was also a major reduction in heart scarring."

In 33 patients with heart failure who had undergone coronary artery bypass surgery, researchers removed a tiny piece of heart tissue and isolated heart stem cells called c-kit CSCs. Researchers then grew additional cells to infuse into 20 volunteers assigned to treatment.

Among outcomes found two years after treatment:

"We have not seen any deaths among the patients, or any adverse effects that can be ascribed to the stem cells," Bolli said.

About 6.6 million Americans suffer from heart failure, according to the American Heart Association. Life expectancy is about five years after diagnosis. Ischemic heart attacks cause most of the 57,000 U.S. deaths a year due to heart failure.

Larger, multi-center studies are needed to confirm the findings, Bolli said.

The Jewish Hospital, University of Louisville, and the National Institutes of Health funded the study. Co-authors' names are on the abstract.

Read more:
Cardiac Stem Cells May Help Treat Heart Failure

Keynote Speaker: Daniel Kraft bull; Presented by SPEAK Inc.
Stanford and Harvard Trained Physician-Scientist, Inventor, Entrepreneur and Innovator Dr. Daniel Kraft has over 20 years of experience in clinical practice, biomedical research and healthcare innovation. Daniel chairs the Medicine track for Singularity University and is Executive Director for FutureMed, a program which explores convergent, exponentially developing technologies and their potential in biomedicine and healthcare. Following undergraduate degrees at Brown and medical school at Stanford, Dr. Kraft was board certified in the Harvard combined Internal Medicine and Pediatrics residency program at the Massachusetts General Hospital and Boston Children`s Hospital. He went on to complete Stanford fellowships in hematology/oncology bone marrow transplantation, and extensive research in stem cell biology and regenerative medicine. He has multiple scientific publications (including in Nature and Science), medical device, immunology and stem cell related patents through faculty positions with Stanford University School of Medicine and as clinical faculty for the pediatric bone marrow transplantation service at UCSF. Dr. Kraft recently founded IntelliMedicine, focused on enabling connected, data driven, and integrated personalized medicine. He is also the inventor of the MarrowMiner, an FDA approved device for the minimally invasive harvest of bone marrow, and founded RegenMed Systems, a company developing technologies to enable adult stem cell based regenerative ...From:speakincViews:0 0ratingsTime:14:53More inPeople Blogs

See the rest here:
Keynote Speaker: Daniel Kraft • Presented by SPEAK Inc. - Video

The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver
ll4.me The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver A look at the forefront of an industry revolution ""I #39;ve been deep inside the biotech industry since its infancy. This book provides fresh insights about how it started, what drives it, and most importantly, where it #39;s going.""--Scott W. Morrison, partner, Ernst Young LL Richard W. Oliver predicted the onset of a new era with The Coming Biotech Age. Now that age is here--and companies are reaping the benefits of this incredible new revolution. As biotech companies become the new economic engines of growth and innovation, businesses must have access to the latest developments of this area of research. In a special revised edition, now titled The Biotech Age, Oliver has created the first practical guide to this fascinating realm of scientific development. With updated information on the latest research, examples of biotech breakthroughs, and a close examination of current biotech issues such as cloning and stem cell research, The Biotech Age presents an accessible overview of the business of biotechnology and its vast implications and opportunities for all types of industries. This is a topic no one can afford to miss--especially future-minded executives and investors in cutting-edge technologies.Words: and opportunities, companies it, how deep is, inside from, it must have, must have it, young ernstAuthor: Oliver, Richard Publisher: McGraw-Hill Illustration: N Language: ENG Title ...From:jonisims9854Views:0 0ratingsTime:00:10More inPeople Blogs

Link:
The Biotech Age: The Business Of Biotech And How To Profit From It - Richard Oliver - Video